BRAF and neoplasm: Several tumors harboring genomic alterations with FDA-approved indications in other tumor types were found including pathogenic PIK3CA, EGFR Exon 19/20 insertions, KRAS G12C (N = 1), FGFR fusions (N = 1), BRAF V600E mutations (N = 4), and BRCA2 (N = 1) (Table 3).